SITC's Guide to Managing Immunotherapy Toxicity

By:

Ernstoff, Marc (ed)

Contributor(s):

Publication details: United States : Springer, 2019ISBN:

0826172148
9780826172143

Subject(s):

Contents:

Overview of Anti-CLA-4 agents - ipilimunab and tremelimumab; Overview of PD-1 and PD-L1 inhibitors; Indication and toxicities of immune checkpoint inhibitor combinations; General principles of immune-related toxicities; Dermatologic toxicities - rash, mucosal irritation, and pruritus; Muskuloskeletal and rheumatologic toxicities; Immune-related gastrointestinal toxicities; Pneumotoxicity associated with immune checkpoint blockades; Immune-related endocrinopathies associated with immune checkpoint inhibitors; Neurologic adverse events and neurologic complications; Cardiovascular toxicities related to immune checkpoint inhibitors; Renal toxicities associated with immune checkpoint inhibitors; Haematologic toxicities of apparent immune-related origins; Ocular toxicities caused by immune dysregulation; Safety and regulation of immune checkpoint inhibitors in special patient populations; Cancer-related fatigue in patients of immune checkpoint inhibitor therapy; Cost-effectiveness and financial toxicity of new cancer therapies

Summary: SITC's Guide to Managing Immunotherapy Toxicity is a practical reference to managing side effects associated with FDA-approved cancer immunotherapy drugs

Holdings
Item type	Home library	Class number	Status	Date due	Barcode
Book	David Adams Library (Royal Marsden) Shelves	QZ200 ERN (Browse shelf(Opens below))	Available		0000007682

SITC's Guide to Managing Immunotherapy Toxicity is a practical reference to managing side effects associated with FDA-approved cancer immunotherapy drugs

There are no comments on this title.

to post a comment.